Successful stem cell collection for atypical teratoid rhabdoid tumor in an extremely low‐body weight child: A case report

Abstract

AbstractThe use of peripheral blood hematopoietic stem cells for bone marrow reconstitution after myeloablative therapy is well established in children with malignant disorders. However, the peripheral blood hematopoietic stem cells collection in very low‐body weight (≤10 kg) children remains a significant challenge because of technical and clinical issues. A male newborn affected by atypical teratoid rhabdoid tumor, diagnosed prenatally, received two cycles of chemotherapy following surgical resection. After an interdisciplinary discussion, it was decided to intensify the treatment with high‐dose chemotherapy followed by autologous stem cell transplantation. After 7 days of G‐CSF administration the patient underwent hematopoietic progenitor cells‐apheresis collection. The procedure was performed in the pediatric intensive care unit, using two central venous catheters and Spectra Optia device. The cell collection procedure was completed in 200 min, during which time 3.9 total blood volumes were processed. During apheresis we did not observe electrolyte alterations. No adverse events were recorded during or immediately following the cell collection procedure. Our report describes the feasibility of performing large volume leukapheresis without complications in an extremely low‐body weight patient weighing 4.5 kg using the Spectra Optia apheresis device. No catheter‐related problems occurred, and apheresis was completed without any adverse event. In conclusion, we believe that very low‐body weight pediatric patients need a multidisciplinary approach to manage central venous access, hemodynamic monitoring, cell collection, prevention of metabolic complications to improve safety, feasibility, and efficiency of stem cell collection procedures.